Use of fosfluridine tidoxil (FT) for the treatment of intraepithelial proliferative diseases
申请人:Boehm Erwin
公开号:US20080014258A1
公开(公告)日:2008-01-17
The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic keratosis. The Fosfluridine Tidoxil can be systemically administered alone or in combination with topical treatment agents.
本发明涉及系统给药福斯氟尿苷替多昔尔(5-氟尿苷)-5′-磷酸(3-十二烷基巯基-2-癸氧基)丙酯或其盐,用于治疗如日光性角化症等上皮内增生性疾病。福斯氟尿苷替多昔尔可以单独系统给药,或与局部治疗药物联合使用。